CPX-351 IN PATIENTS 60-75 YEARS OF AGE WITH AML
What is the purpose of this trial?
To confirm the efficacy of CPX-351 compared to (7+3) as first line therapy in elderly patients (60-75 years) with high risk (secondary) AML. The primary efficacy endpoint will be overall survival.
- 60 Years and older
- Celator Pharmaceuticals, Inc.
- Last Updated:
- Study HIC#: